Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | F13A1 | P00488 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | THPO | P40225 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11158148 | 0.81 | GSR (0.50) | MAOAMAOBALOX15LMNAMEN1 | |
| SCHEMBL17642008 | 0.81 | GSR (0.50) | MAOAMAOBALOX15LMNAMEN1 | |
| SCHEMBL14363914 | 0.78 | GSR (0.41) | MAOAMAOBCYP1A2ALOX15TSHR | |
| SCHEMBL31396832 | 0.78 | GSR (0.41) | MAOAMAOBCYP1A2ALOX15TSHR | |
| SCHEMBL28611239 | 0.78 | MAOA (0.50) | MAOAMAOBCA12F13A1CA2 | |
| SCHEMBL888253 | 0.76 | CA12 (0.50) | MAOAMAOBCA12F13A1CA2 | |
| SCHEMBL117478 | 0.74 | CA12 (0.62) | CA12F13A1CA2CYP1A2ALOX15 | |
| SCHEMBL6536558 | 0.74 | MAOA (0.72) | MAOAMAOBCA12F13A1CA2 | |
| SCHEMBL26309125 | 0.74 | GSR (0.64) | MAOAMAOBCA12F13A1CA2 | |
| SCHEMBL1046120 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403840-B2 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20150368258-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2015-12-24 | — | — | US | disclosed |
| US-9216989-B2 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2015-12-22 | — | — | US | disclosed |
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | IMBERT THIERRY | 2011-03-03 | — | — | US | disclosed |
| US-7846926-B2 | (Poly)aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2010-12-07 | — | — | US | disclosed |
| CN-1946727-B | (Poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents | PF MEDICAMENT | 2010-08-11 | — | — | CN | disclosed |
| US-20090170843-A1 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PIERRE FABRE MEDICAMENT (FR) | 2009-07-02 | — | — | US | disclosed |
| EP-1742952-B1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | PF MEDICAMENT (FR) | 2008-07-30 | — | — | EP | disclosed |
| CN-1946727-A | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | PF MEDICAMENT (FR) | 2007-04-11 | — | — | CN | disclosed |
| EP-1742952-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN, THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005100363-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | PIERRE FABRE MEDICAMENT (FR) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368258-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | NPEPPS, PTMA, PARN | MAOA 2659/4885MAOB 2747/4885CA12 3501/4885 |
| US-20110053967-A1 | (POLY) AMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN THEIR PROCESS OF PREPARATION AND THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENTS | NPEPPS, PTMA, PARN | MAOA 2659/4885MAOB 2747/4885CA12 3501/4885 |
| US-20090170843-A1 | (Poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents | NPEPPS, PTMA, PARN | MAOA 2659/4885MAOB 2747/4885CA12 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.